PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Clinical trial NCT05034536 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05034536
- Sponsor
- Massachusetts General Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-07
- Primary completion
- 2026-06-30
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.